Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONA-XR (onapristone) is a selective progesterone receptor (PR) antagonist designed to block both ligand dependent and ligand-independent activity of PR which downregulates cancer stem cellmobilization, and blocking immune evasion.
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onapristone,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor (PR) that is orally administered. Preclinical and clinical data suggest that ONA-XR has anticancer activity by inhibiting progesterone receptor binding...
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2022
Lead Product(s) : Onapristone,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onapristone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of PR, a key unchecked mechanism in hormone-driven women’s cancers.The preclinical data for onapristone (ONA-XR) support it as a potent progesterone ...
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : Onapristone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onapristone,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor (PR) that is orally administered. Currently, there are no approved therapies that selectively target PR+ cancers.
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Onapristone,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onapristone
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONA-XR (onapristone extended release), a potent, specific progesterone receptor (PR) antagonist being evaluated for PR+ breast, ovarian and endometrial cancer, and our preclinical anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for gynecolo...
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : Onapristone
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Context Therapeutics Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
Details : Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR (onapristone extended release) demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary.
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2022
Lead Product(s) : Onapristone,Anastrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onapristone,Letrozole,Palbociclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Menarini
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor (PR) that is orally administered. ONA-XR is an investigational drug that has not been approved for marketing by any regulatory authority.
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 08, 2022
Lead Product(s) : Onapristone,Letrozole,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Menarini
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Onapristone
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data demonstrated ONA-XR (Onapristone extended release) decreased proliferation in tumors with high PR+ at baseline in early breast cancer.
Product Name : ONA-XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2021
Lead Product(s) : Onapristone
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onapristone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Context Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2021
Lead Product(s) : Onapristone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Context Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Onapristone
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Context Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2021
Lead Product(s) : Onapristone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Context Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable